Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLY0H5)

• Drug Name: Astuprotimut-R Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMLY0H5

Molecule-Related Drug Atlas

Drug(s) Targeting Melanoma-associated antigen 3 (MAGEA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[3]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[4]
GL-0817	DM17OZM	Head and neck cancer	2D42	Phase 2	[5]
KITE-718	DMBSI6Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanoma-associated antigen 3 (MAGEA3)	TTWSKHD	MAGA3_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00796445) A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 600553).
• [3] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [4] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
• [7] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.